Related references
Note: Only part of the references are listed.Improvement in Hematopoiesis after Iron Chelation Therapy with Deferasirox in Patients with Aplastic Anemia
Sung-Eun Lee et al.
ACTA HAEMATOLOGICA (2013)
The effect of iron overload and chelation on erythroid differentiation
Kazuki Taoka et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2012)
Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: A brief review
Roberto Guariglia et al.
LEUKEMIA RESEARCH (2011)
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias
Maria Domenica Cappellini et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Deferasirox is a powerful NF-κB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging
Emanuela Messa et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes
Hussam Ghoti et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients
Esther Natalie Oliva et al.
TRANSFUSION (2010)
Early Deferasirox Treatment in a Patient with Myelodysplastic Syndrome Results in a Long-Term Reduction in Transfusion Requirements
Silvana Capalbo et al.
ACTA HAEMATOLOGICA (2009)
Transfusion independence in Diamond-Blackfan anemia after deferasirox therapy
Ali T. Taher et al.
ANNALS OF HEMATOLOGY (2009)
Deferasirox Treatment Improved the Hemoglobin Level and Decreased Transfusion Requirements in Four Patients with the Myelodysplastic Syndrome and Primary Myelofibrosis
E. Messa et al.
ACTA HAEMATOLOGICA (2008)
A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade®, ICL670) in patients with transfusion-dependent anemias and iron-overload:: a Phase I study in Japan
Keisuke Miyazawa et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2008)
Long-term response and outcome following immuno-suppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group
Makoto Hirokawa et al.
HAEMATOLOGICA (2007)
Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology
M. Dungarwalla et al.
ANNALS OF HEMATOLOGY (2007)
Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience
Carrie A. Thompson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia
WY Au et al.
LEUKEMIA RESEARCH (2005)
The effect of treatment with Campath-1H in patients with autoimmune cytopenias
F Willis et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia
M Zecca et al.
BLOOD (2001)
Share Paper
